Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CCKAR | P32238 | 5/20 | 0.55 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 4/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835708 | 0.93 | CCKAR (0.51) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL6834101 | 0.85 | NHERF1 (0.56) | NHERF1 | |
| SCHEMBL6834154 | 0.84 | KMT2A (0.49) | NPC1RAB9ANHERF1 | |
| SCHEMBL6835826 | 0.83 | KDM4E (0.61) | NPC1RAB9ANHERF1 | |
| SCHEMBL6834270 | 0.83 | FLT3 (0.50) | NPC1RAB9ACCKARNHERF1CCKBR | |
| SCHEMBL6833112 | 0.83 | KDM4E (0.57) | NPC1RAB9ANHERF1BCAT1 | |
| SCHEMBL13701154 | 0.82 | NHERF1 (0.74) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL6818302 | 0.82 | NSD2 (0.58) | NPC1RAB9ANHERF1 | |
| SCHEMBL6833085 | 0.82 | ALB (0.43) | NHERF1 | |
| SCHEMBL6830559 | 0.82 | NHERF1 (0.45) | NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NPC1 3778/4885LMNA 3376/4885RAB9A 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.